Factors Associated with Biochemical Remission after Microscopic Transsphenoidal Surgery for Acromegaly

 

 Buy Article Permissions and Reprints

Abstract

Objectives To analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (TSS) for a growth hormone (GH)-secreting adenoma.

Design A 6-year retrospective review of 86 consecutive acromegaly surgeries.

Setting Procedures performed at a single institution by a single surgeon.

Participants Seventy acromegaly patients.

Main Outcome Measures Demographic information, preoperative laboratory values, tumor imaging data, and morphological and immunohistochemical data were collected. Predictive values using the latest and most stringent biochemical remission criteria were determined using univariate and multivariate statistical analyses.

Results Remission rate for 59 (18 males) acromegaly patients meeting the study inclusion criteria was 52.5%. Remission rates for micro- and macroadenomas were 81.8% and 45.8%, respectively. Patients of older age, with a smaller tumor, lower Knosp grade, lower preoperative GH, and insulinlike growth factor 1 levels were more likely to achieve remission. Remission rate decreased significantly with repeat surgeries. Those patients with adenomas that stained positive for somatostatin receptor subtype 2A were less likely to experience tumor recurrence and more likely to respond to medical treatment with persistent or elevated GH hypersecretion.

Conclusions Microscopic TSS continues to be a viable means for treating acromegaly patients. Patients should be followed long term.

• References

• 1 Baris D, Gridley G, Ron E , et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 2002; 13 (5) 395-400
  CrossrefPubMedGoogle Scholar
• 2 Bynke O, Karlberg BE, Kågedal B, Nilsson OR. Early post-operative growth hormone levels predict the result of transsphenoidal tumour removal in acromegaly. Acta Endocrinol (Copenh) 1983; 103 (2) 158-162
  PubMedGoogle Scholar
• 3 Melmed S. Medical progress: acromegaly. N Engl J Med 2006; 355 (24) 2558-2573
  CrossrefPubMedGoogle Scholar
• 4 Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41 (1) 95-102
  CrossrefPubMedGoogle Scholar
• 5 Webb SM, Casanueva F, Wass JA. Oncological complications of excess GH in acromegaly. Pituitary 2002; 5 (1) 21-25
  CrossrefPubMedGoogle Scholar
• 6 Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf) 2003; 58 (1) 86-91
  CrossrefPubMedGoogle Scholar
• 7 Campbell PG, Kenning E, Andrews DW, Yadla S, Rosen M, Evans JJ. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29 (4) E5
  PubMedGoogle Scholar
• 8 Cappabianca P, Cavallo LM, Colao A , et al. Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg 2002; 45 (4) 193-200
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Cook DM, Ezzat S, Katznelson L , et al; AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004; 10 (3) 213-225
  CrossrefPubMedGoogle Scholar
• 10 De P, Rees DA, Davies N , et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 2003; 88 (8) 3567-3572
  CrossrefPubMedGoogle Scholar
• 11 Dehdashti AR, Ganna A, Karabatsou K, Gentili F. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series. Neurosurgery 2008; 62 (5) 1006-1015 ; discussion 1015–1017
  CrossrefPubMedGoogle Scholar
• 12 Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004; 89 (2) 495-500
  CrossrefPubMedGoogle Scholar
• 13 Jane Jr JA, Starke RM, Elzoghby MA , et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011; 96 (9) 2732-2740
  CrossrefPubMedGoogle Scholar
• 14 Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations. Neuroendocrinology 2006; 83 (3-4) 230-239
  CrossrefPubMedGoogle Scholar
• 15 Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure.'. Eur J Endocrinol 2005; 152 (3) 379-387
  CrossrefPubMedGoogle Scholar
• 16 Shimon I, Cohen ZR, Ram Z, Hadani M. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001; 48 (6) 1239-1243 ; discussion 1244–1245
  PubMedGoogle Scholar
• 17 Yano S, Kawano T, Kudo M , et al. Endoscopic endonasal transsphenoidal approach through the bilateral nostrils for pituitary adenomas. Neurol Med Chir (Tokyo) 2009; 49 (1) 1-7
  CrossrefPubMedGoogle Scholar
• 18 Giustina A, Barkan A, Casanueva FF , et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85 (2) 526-529
  CrossrefPubMedGoogle Scholar
• 19 Giustina A, Chanson P, Bronstein MD , et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95 (7) 3141-3148
  Google Scholar
• 20 Arafat AM, Möhlig M, Weickert MO , et al. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 2008; 93 (4) 1254-1262
  CrossrefPubMedGoogle Scholar
• 21 Fleseriu M, Delashaw Jr JB, Cook DM. Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus 2010; 29 (4) E15
  PubMedGoogle Scholar
• 22 Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2012;
  PubMedGoogle Scholar
• 23 Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 2012; 76 (1) 96-102
  CrossrefPubMedGoogle Scholar
• 24 Kato M, Inoshita N, Sugiyama T , et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J 2012; 59 (3) 221-228
  CrossrefPubMedGoogle Scholar
• 25 Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 2010; 29 (4) E2
  PubMedGoogle Scholar
• 26 Osamura RY, Kajiya H, Takei M , et al. Pathology of the human pituitary adenomas. Histochem Cell Biol 2008; 130 (3) 495-507
  CrossrefPubMedGoogle Scholar
• 27 Lee EJ, Ahn JY, Noh T, Kim SH, Kim TS, Kim SH. Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma?. Neurosurgery 2009; 64 (3, Suppl): ons62-ons69 ; discussion ons69–ons70
  CrossrefPubMedGoogle Scholar
• 28 Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993; 33 (4) 610-617 ; discussion 617–618
  CrossrefPubMedGoogle Scholar
• 29 Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue [in German]. Pathologe 1987; 8 (3) 138-140
  PubMedGoogle Scholar
• 30 Frank G, Pasquini E. Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas. Front Horm Res 2006; 34: 64-82
  PubMedGoogle Scholar
• 31 Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M, Ferraz T. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center. Neurosurg Focus 2010; 29 (4) E7
  PubMedGoogle Scholar
• 32 Hofstetter CP, Mannaa RH, Mubita L , et al. Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010; 29 (4) E6
  PubMedGoogle Scholar
• 33 Kabil MS, Eby JB, Shahinian HK. Fully endoscopic endonasal vs. transseptal transsphenoidal pituitary surgery. Minim Invasive Neurosurg 2005; 48 (6) 348-354
  Article in Thieme ConnectPubMedGoogle Scholar
• 34 Rudnik A, Zawadzki T, Wojtacha M , et al. Endoscopic transnasal transsphenoidal treatment of pathology of the sellar region. Minim Invasive Neurosurg 2005; 48 (2) 101-107
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Tabaee A, Anand VK, Barrón Y , et al. Endoscopic pituitary surgery: a systematic review and meta-analysis. J Neurosurg 2009; 111 (3) 545-554
  CrossrefPubMedGoogle Scholar
• 36 Wilson TJ, McKean EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications. Pituitary 2013;
  PubMedGoogle Scholar
• 37 Nishioka H, Haraoka J. Biochemical cure of acromegaly after transsphenoidal surgery despite residual tumor on magnetic resonance imaging: case report. Neurol Med Chir (Tokyo) 2008; 48 (7) 311-313
  CrossrefPubMedGoogle Scholar